Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Interactive Cardiovascular and Thoracic Surgery

Volumn 15, Issue 4, 2012, Pages 690-695

  Okonta, Kelechi E ^a   Edwin, Frank ^b   Falase, Bode ^c  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b KORLE BU TEACHING HOSPITAL   (Ghana)

^c LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

Excessive bleeding; Paediatric cardiac surgery; Recombinant activated factor VII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

CAUSE OF DEATH; CHEST TUBE; CHILD HEALTH CARE; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART SURGERY; HEMOSTASIS; HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THORAX DRAINAGE; THROMBIN TIME; THROMBOEMBOLISM; THROMBOSIS;

ADOLESCENT; AGE FACTORS; BENCHMARKING; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; COAGULANTS; EVIDENCE-BASED MEDICINE; FACTOR VIIA; HEART DEFECTS, CONGENITAL; HEMOSTATIC TECHNIQUES; HUMANS; INFANT; INFANT, NEWBORN; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84869413830     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs309     Document Type: Conference Paper

References (17)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: Best BETS. Interact CardioVasc Thorac Surg 2003;2:405-9.
2. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factorVII in paediatric cardiac surgery. Intensive Care Med 2004;4:682-5.
3. Kylasam S, Mos K, Fijtin S, Webster B, Chard R, Egan J. Recombinant activated factor VII following pediatric cardiac surgery. J Intensive Care Med 2009;2:116-21.
4. Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004;3:246-50.
5. Tobias JD, Simic JM, Weinstein S, Schechter W, Kartha V, Michler RE. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 2004;5:270-3.
6. Niles SD, Burkhart HM, Duffey DA, Buhrman K, Burzynski J, Holt DW. Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery. J Extra Corpor Technol 2008;4:241-8.
7. Veldman A, Neuhaeuser C, Akintuerk H, Thul J, Gehron J, Schranz D et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007;12:1176-81.
8. Agarwal HS, Bennett JE, Churchwell KB, Christian KG, Drinkwater DC Jr, He Y et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007;1:161-8.
9. Singh SP, Chauhan S, Choudhary M, Vasdev S, Talwar S. Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery. Asian Cardiovasc Thorac Ann 2012;1:19-23.
10. Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 2005;3:234-40.
11. Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth 2009;4:364-70.
12. Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: A single institution experience. Ann Thorac Surg 2010;2:570-6.
13. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006;5:389-95.
14. Warren OJ, Rogers PL, Watret AL, de Wit KL, Darzi AW, Gill R et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here? Pediatr Crit Care Med 2009;5:572-82.
15. McEwan A. Aspects of bleeding after cardiac surgery in children. Paediatr Anaesth 2007;17:1126-33.
16. Kern FH, Morana NJ, Sears JJ, Hackey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992;54:541-6.
17. Tanos M, Dunning J. Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery. Interact CardioVasc Thorac Surg 2006;4:493-8.